This HTML5 document contains 51 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dbpedia-dehttp://de.dbpedia.org/resource/
n14https://www.cdc.gov/ncidod/diseases/hanta/hps/noframes/phys/
dbpedia-dahttp://da.dbpedia.org/resource/
dcthttp://purl.org/dc/terms/
n5http://www.viprbrc.org/brc/
yago-reshttp://yago-knowledge.org/resource/
n12http://ml.dbpedia.org/resource/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
n25http://www.expasy.org/viralzone/all_by_species/
n28https://global.dbpedia.org/id/
yagohttp://dbpedia.org/class/yago/
dbthttp://dbpedia.org/resource/Template:
rdfshttp://www.w3.org/2000/01/rdf-schema#
freebasehttp://rdf.freebase.com/ns/
n7http://bn.dbpedia.org/resource/
dbpedia-nohttp://no.dbpedia.org/resource/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
dbpedia-vihttp://vi.dbpedia.org/resource/
n24http://www.plospathogens.org/article/info:doi/10.1371/
wikipedia-enhttp://en.wikipedia.org/wiki/
dbphttp://dbpedia.org/property/
provhttp://www.w3.org/ns/prov#
dbchttp://dbpedia.org/resource/Category:
xsdhhttp://www.w3.org/2001/XMLSchema#
wikidatahttp://www.wikidata.org/entity/
goldhttp://purl.org/linguistics/gold/
dbrhttp://dbpedia.org/resource/

Statements

Subject Item
dbr:Hantavirus_vaccine
rdf:type
yago:State100024720 yago:Condition113920835 yago:PathologicalState114051917 dbo:Drug yago:Abstraction100002137 yago:WikicatHantavirusInfections yago:Attribute100024264 yago:Infection114174549 yago:IllHealth114052046 yago:PhysicalCondition114034177
rdfs:label
Hantavirusimpfstoff Hantavirus vaccine
rdfs:comment
Ein Hantavirusimpfstoff ist ein Impfstoff gegen Infektionen mit Hantaviren. Hantavirus vaccine is a vaccine that protects in humans against hantavirus infections causing hantavirus hemorrhagic fever with renal syndrome (HFRS) or hantavirus pulmonary syndrome (HPS). The vaccine is considered important as acute hantavirus infections are responsible for significant morbidity and mortality worldwide. It is estimated that about 1.5 million cases and 46,000 deaths occurred in China from 1950 to 2007. The number of cases is estimated at 32,000 in Finland from 2005 to 2010 and 90,000 in Russia from 1996 to 2006.
dct:subject
dbc:Hantavirus_infections dbc:Vaccines
dbo:wikiPageID
41027768
dbo:wikiPageRevisionID
1091161880
dbo:wikiPageWikiLink
dbr:Seoul_virus dbr:List_of_vaccine_topics dbr:Vaccine-naive dbr:Phases_of_clinical_research dbr:Gou_virus dbr:Hantavirus_hemorrhagic_fever_with_renal_syndrome dbc:Vaccines dbr:Hantavirus_pulmonary_syndrome dbc:Hantavirus_infections dbr:Hantaan_River_virus
dbo:wikiPageExternalLink
n5:home.do%3Fdecorator=bunya n14:technicalinfoindex.htm n5:viprStrainDetails.do%3FncbiAccession=AM998808&decorator=bunya&context=1312898403892 n24:journal.ppat.1003159 n25:213.html
owl:sameAs
n7:হান্তাভাইরাস_ভ্যাক্সিন dbpedia-vi:Vắc-xin_Hantavirus n12:ഹാൻ‌ടവൈറസ്_വാക്സിൻ wikidata:Q17138123 dbpedia-da:Hantavirusvaccine dbpedia-no:Hantavirusvaksine dbpedia-de:Hantavirusimpfstoff yago-res:Hantavirus_vaccine freebase:m.0z2n8ly n28:gVtQ
dbp:wikiPageUsesTemplate
dbt:Vaccines dbt:Reflist
dbo:abstract
Hantavirus vaccine is a vaccine that protects in humans against hantavirus infections causing hantavirus hemorrhagic fever with renal syndrome (HFRS) or hantavirus pulmonary syndrome (HPS). The vaccine is considered important as acute hantavirus infections are responsible for significant morbidity and mortality worldwide. It is estimated that about 1.5 million cases and 46,000 deaths occurred in China from 1950 to 2007. The number of cases is estimated at 32,000 in Finland from 2005 to 2010 and 90,000 in Russia from 1996 to 2006. The first hantavirus vaccine was developed in 1990 initially for use against Hantaan River virus which causes one of the most severe forms of HFRS. It is estimated that about two million doses of rodent brain or cell-culture derived vaccine are given in China every year. The wide use of this vaccine may be partly responsible for a significant decrease in the number of HFRS cases in China to less than 20,000 by 2007. Other hantaviruses for which the vaccine is used include Seoul (SEOV) virus. However the vaccine is thought not to be effective against European hantaviruses including Puumala (PUUV) and Dobrava-Belgrade (DOBV) viruses. The pharmaceutical trade name for the vaccine is Hantavax. As of 2012 no hantavirus vaccine have been approved for use in Europe or USA. A phase 2 study on a human HTNV/PUUV DNA hantavirus vaccine is ongoing. In addition to Hantavax three more vaccine candidates have been studied in I–II stage clinical trials. They include a recombinant vaccine and vaccines derived from HTNV and PUUV viruses. However, their prospects are unclear Ein Hantavirusimpfstoff ist ein Impfstoff gegen Infektionen mit Hantaviren.
gold:hypernym
dbr:Vaccine
prov:wasDerivedFrom
wikipedia-en:Hantavirus_vaccine?oldid=1091161880&ns=0
dbo:wikiPageLength
3696
foaf:isPrimaryTopicOf
wikipedia-en:Hantavirus_vaccine